This section is intended for UK healthcare professionals. If you are a member of the public click here. If you have been prescribed Ninlaro click here.

EFFICACY

Adding oral NINLARO to Rd significantly extends PFS in RRMM patients treated with 2–3 prior lines of therapy5

In the ITT population at 14.7 months’ median follow-up, oral NINLARO + Rd demonstrated superior PFS rates vs placebo+ Rd (HR 0.742 (95% Cl 0.587, 0.939; p=0.012))1

  • In the pre-defined, stratified subgroup of patients who received 2–3 prior lines of therapy, PFS was significantly extended for NINLARO + Rd versus placebo + Rd (median not reached vs 12.9 months; HR 0.58, 95% CI 0.40–0.84, p=0.0033)5*
  • At 23 months' median follow-up, median OS was not reached for either group (HR 0.65, 95% CI 0.41–1.02)6

Adding oral NINLARO to Rd significantly extends PFS in RRMM patients

Adapted from Mateos et al. 2017.

*At 14.7 months' median follow-up in the ITT population

Adding oral NINLARO to Rd extends PFS across a broad group of patients vs placebo + Rd1,2

  • A favourable effect on PFS with NINLARO + Rd was observed across a broad range of patients including:1,2
    • High‑risk cytogenetics
    • 2 to 3 prior lines
    • Prior Pl exposure
    • Mild-to-moderate renal impairment
  • As multiple myeloma is a heterogeneous disease, benefit may vary across subgroups2

Adding oral NINLARO to Rd extends PFS vs placebo + Rd across a broad group of patients1,2

Adapted from NINLARO Summary of Product Characteristics1

*Defined as patients with del(17), t(4;14), or t(14;16)1

This study was not powered to show significance in PFS across these prespecified subgroups

*At 14.7 months' median follow-up in the ITT population

Adding oral NINLARO to Rd extends PFS irrespective of patients' cytogenetic risk profile3

Adding oral NINLARO to Rd maintained the median PFS in patients with high‑risk cytogenetics, including those with del(17), to a similar level as standard risk patients3†

Adapted from Avet-Loiseau et al. 20163

† Clinical laboratory evaluations for high‑risk cytogenetic markers, including del(17), t(4;14), and t(14;16) were performed by a central laboratory. Positivity for del(17), t(4;14) and t(14;16) were defined by a percentage of positive cells that were above the technical background cut-offs of 5%, 3% and 3% respectively

*At 14.7 months' median follow-up in the ITT population

Oral NINLARO + Rd patients responded rapidly2

Oral NINLARO + Rd patients responded after a median of ~1 cycle2‡

Adapted from NINLARO Summary of Product Characteristics2

‡ The duration of one cycle of NINLARO + Rd is 28 days

¥ Response of ≥PR

*At 14.7 months' median follow-up in the ITT population

Oral NINLARO + Rd patients' responses deepened with sustained treatment4

Responses deepened with continued treatment with NINLARO + Rd4‡

Adapted from Supplementary Appendix to Moreau et al. 20164

‡The duration of one cycle of NINLARO + Rd is 28 days

*At 14.7 months' median follow-up in the ITT population